HDAC9 and cancer: The research data support the testing of bortezomib/romidepsin as a potential therapeutic regimen for metastatic or recurrent GC and provide novel insight into the mechanism of synergistic action between proteasome and HDAC inhibitors in the induction of autophagic cell death of cancer cells.